Status:
RECRUITING
Hitting the Mark: Introducing State-of-the-art MRI for Precision Radiotherapy of Glioblastoma
Lead Sponsor:
Erasmus Medical Center
Conditions:
Glioblastoma
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The goal of this prospective cohort study is to assess the potential of advanced MRI for improved radiotherapy target delineation in patients diagnosed with glioblastoma. The main questions it aims to...
Detailed Description
Rationale: One of the fundamentals of glioblastoma management is radiotherapy, where ionizing radiation is aimed towards a specific target area in the brain to inhibit further tumor growth. As these b...
Eligibility Criteria
Inclusion
- Written informed consent;
- Adult (18 years or older);
- Diagnosed with IDH-wildtype glioblastoma, as confirmed by pathology including molecular analysis post resection/biopsy;
- Referred to the outpatient clinic of the Dept. of Radiotherapy to undergo standard treatment with radiotherapy (30x2 Gy or 15x2.67Gy or 10x3.4Gy).
Exclusion
- Contraindication for (3 Tesla) MRI;
- Contraindication for use of gadolinium-based contrast agent (e.g. subject having renal deficiency or known allergy);
- Referred for treatment of recurrent glioblastoma;
- Previous radiotherapy to the brain;
- Unable to give informed consent
Key Trial Info
Start Date :
January 3 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2026
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT06183983
Start Date
January 3 2024
End Date
August 1 2026
Last Update
June 12 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Erasmus Medical Center
Rotterdam, South Holland, Netherlands, 3015GD